Lv51
860 积分 2024-03-05 加入
PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension
18天前
已完结
Biochemistry of Parkinson's disease 28 years later: a critical review
3个月前
已完结
Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance
3个月前
已完结
Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance
3个月前
已关闭
Effect of fluoxetine on HIF-1α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion
4个月前
已完结
Ritanserin, a serotonin-2 receptor antagonist, inhibits functional recovery after cerebral infarction
4个月前
已完结
Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children With Pulmonary Hypertension: A Pilot Study
5个月前
已完结
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
6个月前
已完结
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
6个月前
已完结
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial
7个月前
已完结
皖公网安备34019202002308
